PL2498756T5 - Preparaty maleinianu neratynibu w postaci tabletki - Google Patents

Preparaty maleinianu neratynibu w postaci tabletki

Info

Publication number: PL2498756T5
Authority: PL; Poland
Prior art keywords: tablet formulations; neratinib maleate; neratinib; maleate; formulations
Prior art date: 2009-11-09

Application number

PL10779339.0T

Other languages

English (en)

Other versions

PL2498756T3 (pl

Inventor

Muhammad Ashraf

Krishnendu Ghosh

Chimanlall Goolcharran

Mainuddin Mahmud

Arwinder Singh Nagi

Original Assignee

Wyeth Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-09

Filing date

2010-11-02

Publication date

2023-04-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43478191&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2498756(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-11-02 Application filed by Wyeth Llc filed Critical Wyeth Llc

2020-03-31 Publication of PL2498756T3 publication Critical patent/PL2498756T3/pl

2023-04-17 Publication of PL2498756T5 publication Critical patent/PL2498756T5/pl

Links

VXZCUHNJXSIJIM-MEBGWEOYSA-N (z)-but-2-enedioic acid;(e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound OC(=O)\C=C/C(O)=O.C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 VXZCUHNJXSIJIM-MEBGWEOYSA-N 0.000 title 1
229950008835 neratinib Drugs 0.000 title 1
239000007916 tablet composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL10779339.0T 2009-11-09 2010-11-02 Preparaty maleinianu neratynibu w postaci tabletki PL2498756T5 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US25940309P	2009-11-09	2009-11-09
PCT/IB2010/054964 WO2011055303A1 (en)	2009-11-09	2010-11-02	Tablet formulations of neratinib maleate
EP10779339.0A EP2498756B2 (en)	2009-11-09	2010-11-02	Tablet formulations of neratinib maleate

Publications (2)

Publication Number	Publication Date
PL2498756T3 PL2498756T3 (pl)	2020-03-31
PL2498756T5 true PL2498756T5 (pl)	2023-04-17

Family

ID=43478191

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL22169771.7T PL4066821T3 (pl)	2009-11-09	2010-11-02	Preparaty maleinianu neratynibu w postaci tabletki
PL10779339.0T PL2498756T5 (pl)	2009-11-09	2010-11-02	Preparaty maleinianu neratynibu w postaci tabletki

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL22169771.7T PL4066821T3 (pl)	2009-11-09	2010-11-02	Preparaty maleinianu neratynibu w postaci tabletki

Country Status (23)

Country	Link
US (2)	US8518446B2 (pl)
EP (4)	EP3566697B1 (pl)
JP (3)	JP5835883B2 (pl)
CN (2)	CN103893140B (pl)
AR (2)	AR078952A1 (pl)
AU (1)	AU2010316683B2 (pl)
CA (1)	CA2780428C (pl)
CY (1)	CY1122330T1 (pl)
DK (2)	DK4066821T3 (pl)
ES (3)	ES2998766T3 (pl)
FI (3)	FI4066821T3 (pl)
FR (1)	FR25C1035I1 (pl)
HR (2)	HRP20192026T4 (pl)
HU (3)	HUE046606T2 (pl)
LT (3)	LT2498756T (pl)
NZ (1)	NZ599763A (pl)
PL (2)	PL4066821T3 (pl)
PT (2)	PT2498756T (pl)
RS (2)	RS59599B2 (pl)
SI (2)	SI2498756T2 (pl)
SM (2)	SMT202500153T1 (pl)
TW (1)	TWI466690B (pl)
WO (1)	WO2011055303A1 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10351448A1 (de) *	2003-11-04	2005-06-09	Bayer Healthcare Ag	Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
CN108421044A (zh)	2005-02-03	2018-08-21	综合医院公司	治疗吉非替尼耐药性癌症的方法
BRPI0618042A2 (pt)	2005-11-04	2011-08-16	Wyeth Corp	usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US9439897B2 (en)	2007-11-06	2016-09-13	Immunolight, Llc	Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
CN102641270A (zh)	2008-06-17	2012-08-22	惠氏有限责任公司	含有hki-272和长春瑞滨的抗肿瘤组合
US8669273B2 (en)	2008-08-04	2014-03-11	Wyeth Llc	Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
IL264349B2 (en)	2009-04-06	2024-01-01	Wyeth Llc	Regimen comprising neratinib for the treatment of cancer
NZ599762A (en) *	2009-11-09	2014-07-25	Wyeth Llc	Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea
FI4066821T3 (fi) *	2009-11-09	2025-05-13	Wyeth Llc	Neratinibimaleaatin tablettiformulaatioita
DK3738434T3 (da)	2011-12-28	2023-12-04	Global Blood Therapeutics Inc	Mellemprodukter til opnåelse af substituerede benzaldehydforbindelser og fremgangsmåder til anvendelse deraf ved øgning af vævsoxygenering
WO2013102145A1 (en)	2011-12-28	2013-07-04	Global Blood Therapeutics, Inc.	Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
AU2014237330A1 (en)	2013-03-15	2015-09-17	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en)	2013-03-15	2019-04-23	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
BR112015021982B1 (pt)	2013-03-15	2022-12-13	Global Blood Therapeutics, Inc	Compostos e seus usos para a modulação de hemoglobina
US9458139B2 (en)	2013-03-15	2016-10-04	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
KR102280614B1 (ko)	2013-03-15	2021-07-21	글로벌 블러드 테라퓨틱스, 인크.	헤모글로빈 조정을 위한 화합물 및 이의 용도
US8952171B2 (en)	2013-03-15	2015-02-10	Global Blood Therapeutics, Inc.	Compounds and uses thereof for the modulation of hemoglobin
US9818967B2 (en) *	2013-06-28	2017-11-14	Universal Display Corporation	Barrier covered microlens films
CN104337782A (zh) *	2013-08-02	2015-02-11	山东新时代药业有限公司	一种甲磺酸伊马替尼片剂
EA201992707A1 (ru)	2013-11-18	2020-06-30	Глобал Блад Терапьютикс, Инк.	Соединения и их применения для модуляции гемоглобина
SI3102208T2 (sl)	2014-02-07	2024-10-30	Global Blood Therapeutics, Inc.	Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida
ES2805008T3 (es)	2014-02-17	2021-02-10	Childrens Nat Medical Ct	Procedimiento y sistema para proporcionar recomendaciones para la ejecución óptima de procedimientos quirúrgicos
DK3172209T3 (da) *	2014-07-25	2021-02-22	Novartis Ag	Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid
WO2017003951A1 (en) *	2015-06-29	2017-01-05	Phloronol, Inc.	Solid pharmaceutical compositions of brown algae
US11020382B2 (en)	2015-12-04	2021-06-01	Global Blood Therapeutics, Inc.	Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
CN106831710A (zh) *	2015-12-07	2017-06-13	常州爱诺新睿医药技术有限公司	一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法
CN106913529B (zh) *	2015-12-24	2020-12-04	江苏恒瑞医药股份有限公司	一种来那替尼或其可药用盐药物组合物的制备方法
CA2937365C (en) *	2016-03-29	2018-09-18	F. Hoffmann-La Roche Ag	Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
AR108435A1 (es)	2016-05-12	2018-08-22	Global Blood Therapeutics Inc	Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
JP2019529534A (ja) *	2016-09-07	2019-10-17	セルジーンコーポレイション	錠剤組成物
TWI778983B (zh) *	2016-10-12	2022-10-01	美商全球血液治療公司	包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN118105392A (zh) *	2017-04-28	2024-05-31	自由生物有限公司	治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
EP3701948A4 (en) *	2017-10-24	2021-08-25	Jiangsu Hengrui Medicine Co., Ltd.	PHARMACEUTICAL COMPOSITION WITH QUINOLINE DERIVATIVE
EP3860975B1 (en)	2018-10-01	2023-10-18	Global Blood Therapeutics, Inc.	Modulators of hemoglobin for the treatment of sickle cell disease
EP4096791A1 (en)	2020-01-31	2022-12-07	Nanocopoeia LLC	Amorphous nilotinib microparticles and uses thereof
US20220378788A1 (en) *	2020-04-30	2022-12-01	Nanocopoeia, Llc	Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
IL297776A (en) *	2020-04-30	2022-12-01	Nanocopoeia Llc	Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
CA3186141A1 (en) *	2020-06-19	2021-12-23	Acerta Pharma B.V.	Acalabrutinib maleate dosage forms
CN116211859A (zh) *	2021-12-03	2023-06-06	江苏奥赛康药业有限公司	一种含有马来酸奈拉替尼的药用组合物及其制备方法
TW202400135A (zh) *	2022-03-07	2024-01-01	美商健生醫藥公司	包含阿替卡普蘭之組成物
TW202345857A (zh) *	2022-03-08	2023-12-01	美商昂科斯克塞爾醫療有限責任公司	他波司他之穩定調配物
EP4682143A1 (en)	2023-03-10	2026-01-21	Convalife Pharmaceuticals Co., Ltd.	Pharmaceutical composition containing egfr inhibitor, and preparation method therefor and use thereof
CN117298116A (zh) *	2023-08-08	2023-12-29	江苏晨泰医药科技有限公司	盐酸佐利替尼制剂
CN117427076B (zh) *	2023-12-05	2025-09-19	中国科学技术大学	来那替尼在制备预防或治疗动脉粥样硬化药物中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW442301B (en) *	1995-06-07	2001-06-23	Sanofi Synthelabo	Pharmaceutical compositions containing irbesartan
US6002008A (en)	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
US6297258B1 (en)	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
US6288082B1 (en)	1998-09-29	2001-09-11	American Cyanamid Company	Substituted 3-cyanoquinolines
US6384051B1 (en)	2000-03-13	2002-05-07	American Cyanamid Company	Method of treating or inhibiting colonic polyps
US7399865B2 (en) *	2003-09-15	2008-07-15	Wyeth	Protein tyrosine kinase enzyme inhibitors
AR046544A1 (es) *	2003-10-15	2005-12-14	Wyeth Corp	Administracion oral de acido [2- (8,9 - dioxo - 2,6 - diazabiciclo [5.2.0] non -1 (7) - en - 2 - il ) alquil] fosfonico yderivados
US20050142192A1 (en) *	2003-10-15	2005-06-30	Wyeth	Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
CN101039952A (zh) *	2004-10-13	2007-09-19	惠氏公司	作为pi3k抑制剂的17－羟基渥曼青霉素类似物
WO2006085168A2 (en) *	2005-01-07	2006-08-17	Ranbaxy Laboratories Limited	Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide
DE602006012972D1 (de) *	2005-04-28	2010-04-29	Wyeth Corp	Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
PL1948180T3 (pl) *	2005-11-11	2013-09-30	Boehringer Ingelheim Int	Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
JP2007169273A (ja) *	2005-11-28	2007-07-05	Takeda Chem Ind Ltd	杵付着を改善した医薬製剤
JP2007211005A (ja) *	2006-01-16	2007-08-23	Ono Pharmaceut Co Ltd	固形製剤用組成物および固形製剤
TW200806282A (en) *	2006-05-05	2008-02-01	Wyeth Corp	Solid dosage formulations
KR20090104862A (ko) *	2007-01-12	2009-10-06	와이어쓰	정제내 정제 조성물
CL2008000280A1 (es) *	2007-02-01	2008-08-18	Takeda Pharmaceutical	Composicion farmaceutica en forma de comprimido que contiene un granulo que comprende un principio activo que induce facilmente a un problema en la compresion y celulosa microcristalina y un auxiliar de compresion que contiene estearato de magnesio y
JP2009089982A (ja) *	2007-10-11	2009-04-30	Ohara Yakuhin Kogyo Kk	打錠用造粒物の造粒方法
US20090203709A1 (en) *	2008-02-07	2009-08-13	Abbott Laboratories	Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
RU2011152105A (ru) *	2009-07-02	2013-08-10	УАЙТ ЭлЭлСи	Составы таблеток 3-цианохинолина и их применение
FI4066821T3 (fi) *	2009-11-09	2025-05-13	Wyeth Llc	Neratinibimaleaatin tablettiformulaatioita

2010
- 2010-11-02 FI FIEP22169771.7T patent/FI4066821T3/fi active
- 2010-11-02 ES ES19154710T patent/ES2998766T3/es active Active
- 2010-11-02 NZ NZ599763A patent/NZ599763A/en unknown
- 2010-11-02 SM SM20250153T patent/SMT202500153T1/it unknown
- 2010-11-02 SI SI201031952T patent/SI2498756T2/sl unknown
- 2010-11-02 ES ES10779339T patent/ES2757882T5/es active Active
- 2010-11-02 SI SI201032155T patent/SI4066821T1/sl unknown
- 2010-11-02 SM SM20190632T patent/SMT201900632T1/it unknown
- 2010-11-02 LT LT10779339T patent/LT2498756T/lt unknown
- 2010-11-02 HU HUE10779339A patent/HUE046606T2/hu unknown
- 2010-11-02 PT PT107793390T patent/PT2498756T/pt unknown
- 2010-11-02 LT LTEP22169771.7T patent/LT4066821T/lt unknown
- 2010-11-02 FI FIEP10779339.0T patent/FI2498756T4/fi active
- 2010-11-02 HR HRP20192026TT patent/HRP20192026T4/hr unknown
- 2010-11-02 WO PCT/IB2010/054964 patent/WO2011055303A1/en not_active Ceased
- 2010-11-02 EP EP19154710.8A patent/EP3566697B1/en active Active
- 2010-11-02 EP EP22169771.7A patent/EP4066821B1/en active Active
- 2010-11-02 CN CN201410082103.7A patent/CN103893140B/zh active Active
- 2010-11-02 HU HUE22169771A patent/HUE071632T2/hu unknown
- 2010-11-02 PL PL22169771.7T patent/PL4066821T3/pl unknown
- 2010-11-02 EP EP10779339.0A patent/EP2498756B2/en active Active
- 2010-11-02 CN CN201080060546.6A patent/CN102724970B/zh active Active
- 2010-11-02 PL PL10779339.0T patent/PL2498756T5/pl unknown
- 2010-11-02 HR HRP20250604TT patent/HRP20250604T1/hr unknown
- 2010-11-02 DK DK22169771.7T patent/DK4066821T3/da active
- 2010-11-02 RS RS20191417A patent/RS59599B2/sr unknown
- 2010-11-02 AU AU2010316683A patent/AU2010316683B2/en active Active
- 2010-11-02 CA CA2780428A patent/CA2780428C/en active Active
- 2010-11-02 RS RS20250477A patent/RS66797B1/sr unknown
- 2010-11-02 PT PT221697717T patent/PT4066821T/pt unknown
- 2010-11-02 DK DK10779339.0T patent/DK2498756T4/da active
- 2010-11-02 EP EP25160646.3A patent/EP4570242A3/en active Pending
- 2010-11-02 ES ES22169771T patent/ES3029208T3/es active Active
- 2010-11-05 US US12/940,808 patent/US8518446B2/en active Active
- 2010-11-08 TW TW99138396A patent/TWI466690B/zh active
- 2010-11-08 JP JP2010249385A patent/JP5835883B2/ja active Active
- 2010-11-09 AR ARP100104156A patent/AR078952A1/es not_active Application Discontinuation
2013
- 2013-08-21 US US13/972,764 patent/US8790708B2/en active Active
2015
- 2015-02-06 JP JP2015021870A patent/JP2015091882A/ja not_active Withdrawn
2017
- 2017-02-06 JP JP2017019429A patent/JP2017075192A/ja not_active Withdrawn
2018
- 2018-11-14 AR ARP180103329A patent/AR114143A2/es not_active Application Discontinuation
2019
- 2019-11-14 CY CY20191101200T patent/CY1122330T1/el unknown
2025
- 2025-08-21 HU HUS2500035C patent/HUS2500035I1/hu unknown
- 2025-08-25 LT LTPA2025531C patent/LTPA2025531I1/lt unknown
- 2025-08-29 FI FIC20250029C patent/FIC20250029I1/fi unknown
- 2025-09-04 FR FR25C1035C patent/FR25C1035I1/fr active Active

Also Published As

Publication number	Publication date
HUS2500035I1 (hu)	2025-09-28
SMT202500153T1 (it)	2025-05-12
ES2998766T3 (en)	2025-02-21
JP2015091882A (ja)	2015-05-14
HRP20192026T1 (hr)	2020-02-07
HUE071632T2 (hu)	2025-09-28
TW201138774A (en)	2011-11-16
CN102724970A (zh)	2012-10-10
ES2757882T3 (es)	2020-04-30
PT4066821T (pt)	2025-06-03
WO2011055303A1 (en)	2011-05-12
RS66797B1 (sr)	2025-06-30
EP4066821B1 (en)	2025-03-05
LTPA2025531I1 (pl)	2025-09-10
ES2757882T5 (es)	2023-05-10
DK2498756T4 (da)	2023-03-20
CA2780428C (en)	2018-02-13
FIC20250029I1 (fi)	2025-08-29
HRP20192026T4 (hr)	2023-03-31
AU2010316683A1 (en)	2012-05-24
CN103893140B (zh)	2016-06-01
SI2498756T2 (sl)	2023-04-28
SI2498756T1 (sl)	2020-01-31
SMT201900632T1 (it)	2020-01-14
PT2498756T (pt)	2019-11-26
SI4066821T1 (sl)	2025-06-30
HUE046606T2 (hu)	2020-03-30
CN103893140A (zh)	2014-07-02
AR078952A1 (es)	2011-12-14
RS59599B1 (sr)	2020-01-31
EP3566697A1 (en)	2019-11-13
EP3566697B1 (en)	2024-09-11
JP5835883B2 (ja)	2015-12-24
HRP20250604T1 (hr)	2025-07-18
CY1122330T1 (el)	2021-01-27
LT2498756T (lt)	2019-12-10
FI4066821T3 (fi)	2025-05-13
US20110111018A1 (en)	2011-05-12
LT4066821T (lt)	2025-05-12
NZ599763A (en)	2014-06-27
FI2498756T4 (fi)	2023-03-22
AU2010316683B2 (en)	2015-10-08
FR25C1035I1 (fr)	2025-11-21
PL4066821T3 (pl)	2025-08-11
CN102724970B (zh)	2014-06-25
JP2011098964A (ja)	2011-05-19
ES3029208T3 (en)	2025-06-23
EP2498756B2 (en)	2023-02-15
EP2498756A1 (en)	2012-09-19
US20140004184A1 (en)	2014-01-02
US8518446B2 (en)	2013-08-27
RS59599B2 (sr)	2023-03-31
US8790708B2 (en)	2014-07-29
DK4066821T3 (da)	2025-04-14
JP2017075192A (ja)	2017-04-20
EP4066821A1 (en)	2022-10-05
DK2498756T3 (da)	2019-11-25
TWI466690B (zh)	2015-01-01
AR114143A2 (es)	2020-07-29
EP2498756B1 (en)	2019-09-04
PL2498756T3 (pl)	2020-03-31
EP4570242A3 (en)	2025-08-20
EP4570242A2 (en)	2025-06-18
CA2780428A1 (en)	2011-05-12

Publication	Publication Date	Title
HUS2500035I1 (hu)	2025-09-28	Neratinib-maleát tabletta készítmények
HUS2000009I1 (hu)	2020-06-29	Kétrétegû tabletta készítmények
PT2498759T (pt)	2018-11-15	Formulações de comprimidos de libertação imediata
SI3061445T1 (sl)	2023-10-30	Visoko koncentrirane farmacevtske formulacije
ZA201200719B (en)	2013-05-29	Pharmaceutical formulation
IL215872A (en)	2016-08-31	Indomethacin preparation
IL213545A0 (en)	2011-07-31	Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
IL213546A0 (en)	2011-07-31	Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
SG10201710156RA (en)	2018-01-30	4-methylpyrazole formulations
EP2473168A4 (en)	2013-04-10	PHARMACEUTICAL FORMULATIONS FOR INDIBULIN
IL219860A0 (en)	2012-07-31	Oral formulation for dexlansoprazole
GB0906003D0 (en)	2009-05-20	Oral drug formulation